Tofacitinib for moderate to severe rheumatoid arthritis

Equality Impact Assessment (Guidance development) (PDF 221 KB)

Final appraisal determination

Final appraisal determination document (PDF 432 KB)

Public committee slides (PDF 407 KB)

Public committee slides (PDF 669 KB)

Committee papers (PDF 14.94 MB)

Final scope (PDF 328 KB)

Final matrix (PDF 255 KB)

Equality impact assessment (Scoping) (PDF 170 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 220 KB)

Draft scope (post-referral) (PDF 360 KB)

Provisional matrix (post-referral) (PDF 256 KB)

Rheumatoid arthritis tofacitinib [ID526]: draft scope for consultation (pre-referral) - November 2011 (PDF 72 KB)

Rheumatoid arthritis tofacitinib [ID526]: provisional matrix (pre-referral) - November 2011 (PDF 37 KB)